VIDEO: Chemotherapy Foundation Symposium ‘didn’t disappoint’

ByRoy Herbst, MD, PhD

In this video, Roy S. Herbst, MD, PhD, associate cancer center director for translational research at Yale Cancer Center, discussed this year’s Chemotherapy Foundation Symposium.

“This year’s Chemo Foundation again didn’t disappoint,” Herbst, who also serves as ensign professor of medicine and professor of pharmacology, and chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital, said.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interview
Kris M. Early-Stage and Locally-Advanced Lung Cancers: Immunotherapy and Targeted Therapy. Presented at: Chemotherapy Foundation Symposium; Nov. 4-6, 2020.

Disclosures: Herbst reports receiving research support from AstraZeneca, Eli Lilly and Company, Genentech/Roche and Merck and Company, and serving as a board member for Junshi Pharmaceuticals and as a consultant for AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol‐Myers Squibb, Cybrexa, Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen and WindMIL Therapeutics. Tsuboi reports receiving honoraria from AstraZeneca KK, Boehringer-Ingelheim Japan, Bristol-Myers Squibb KK, Chugai Pharmaceutical Co., Ltd, Eli Lilly Japan, Johnson & Johnson Japan, Medtronic Japan, MSD, Ono Pharmaceutical Co., Ltd., Taiho Pharma and Teijin Pharma; and research grant/funding to institution from AstraZeneca KK, Boehringer-Ingelheim Japan and MSD.

Take Homes in Lung Cancer

Read more

VIDEO: Chemotherapy Foundation Symposium ‘didn’t disappoint’

Related Content